Join the club for FREE to access the whole archive and other member benefits.

University of Leicester proves feasibility of antibody based targeted senolytics


Key points from article :

Therapy could help fight against the degenerative effects of aging and the diseases associated with it.

New therapy builds on an existing class of drugs called senolytics.

Senolytics must be targeted towards senescent cells whilst leaving healthy cells unaffected.

Researchers designed an antibody-drug conjugate(ADC), targets a membrane marker found on aging cells.

Called B2M, was recently identified as an indicator of senescence in cells.

Antibody binds to the marker to release cytotoxic drug duocarmycin into the cell.

In human cell lines, the antibody was specific for senescent cells.

Professor Salvador Macip says "...the targeted senolytics, which should eliminate senescent cells without affecting the rest"

Research stands as an early proof-of-concept for an antibody targeting approach to senolysis.

Requires further testing to fully identify the mechanisms involved.

Research by University of Leicester published in Scientific Reports.

New study results show clinical applications in pathological ageing

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Associate Professor in Department of Molecular and Cell Biology at University of Leicester.


Scientific Journal providing information from all areas of the natural sciences.


Public research university for UK and international students